For more than two decades, Americans have lived with a peculiar feature of their healthcare system: television commercials in which smiling actors jog through sunlit parks, while a voice rapidly lists side effects ranging from nausea to death. Direct-to-consumer pharmaceutical advertising has become so normalized that it is easy to forget how unusual it is globally.
The United States is effectively the only country in the world that allows this practice. Most advanced nations have concluded that prescription drugs are fundamentally different from ordinary consumer products, and that medical decisions should be guided by physicians and evidence — not billion-dollar advertising campaigns designed to manufacture demand.
At long last, this expensive and harmful practice may finally be under real political pressure.
Across the country, a new bipartisan skepticism is emerging around the role of pharmaceutical advertising in shaping both healthcare costs and medical decision-making. These efforts are not confined to one ideological camp. They reflect a growing consensus across the left, right, and populist movements that the current system is distorting both medicine and markets.
At the federal level, independent Sens. Bernie Sanders (Vt.) and Angus King (Maine) have introduced legislation that would ban prescription drug advertising nationwide. At the same time, Sens. Josh Hawley (R-Mo.) and Jeanne Shaheen (D-N.H.) have advanced bipartisan legislation to eliminate the federal tax deduction for pharmaceutical advertising expenses, ending a taxpayer subsidy for drug marketing.